List of Excipients in Branded Drug DIAZOXIDE ORAL SOLUTION

« Back to Dashboard

Generic Drugs Containing DIAZOXIDE ORAL SOLUTION

Company	Ingredient	NDC	Excipient
TriRx Huntsville Pharmaceutical Services LLC	diazoxide oral suspension	80432-057	ALCOHOL
TriRx Huntsville Pharmaceutical Services LLC	diazoxide oral suspension	80432-057	CARBOXYMETHYLCELLULOSE SODIUM
TriRx Huntsville Pharmaceutical Services LLC	diazoxide oral suspension	80432-057	HYDROCHLORIC ACID
TriRx Huntsville Pharmaceutical Services LLC	diazoxide oral suspension	80432-057	MAGNESIUM ALUMINUM SILICATE

What are the Most Frequently-Used Excipients in DIAZOXIDE ORAL SOLUTION?

# Of NDCs	Excipient
1	ALCOHOL
1	CARBOXYMETHYLCELLULOSE SODIUM
1	HYDROCHLORIC ACID
1	MAGNESIUM ALUMINUM SILICATE

Diazoxide Oral Solution: Excipient Strategy, Regulatory Pathway, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Diazoxide oral liquid is an established but specialized product opportunity. The reference product, Proglycem, is labeled as a 50 mg/mL oral suspension rather than a true solution. The strongest commercial opportunities are a reliable generic suspension, a technically validated true solution or concentrate, improved pediatric dose delivery, and supply assurance for congenital hyperinsulinism. The main barriers are diazoxide’s low aqueous solubility, dose-related gastrointestinal tolerability, preservative control, and the need to demonstrate pharmaceutical equivalence to an established suspension product.[1]

What product is currently marketed as diazoxide oral liquid?

The principal U.S. reference product is Proglycem, diazoxide oral suspension, 50 mg/mL. Diazoxide is used to treat hypoglycemia caused by hyperinsulinism and is also associated with potassium-channel-mediated inhibition of insulin release.[1]

Attribute	Reference-product position
Active ingredient	Diazoxide
Dosage form	Oral suspension
Strength	50 mg/mL
Primary use	Hyperinsulinemic hypoglycemia
Common patient population	Infants, children, and adults with persistent hyperinsulinism
U.S. regulatory status	Prescription drug approved under an NDA
Primary commercial issue	Reliable supply and pediatric administration
True solution status	Not established by the reference label

The distinction between a suspension and a solution is commercially important. A suspension contains dispersed drug particles and requires controlled particle size, redispersibility, sedimentation behavior, and dose uniformity. A true solution requires complete molecular dissolution throughout shelf life. Diazoxide’s limited water solubility makes a solution formulation technically more demanding than a generic suspension.[1,2]

What excipients are used in diazoxide oral suspension?

The Proglycem label identifies a liquid formulation with excipients that support wetting, viscosity, preservation, flavor or mouthfeel, and chemical stability. Product labels and regulatory databases should be used as the controlling sources for the exact qualitative and quantitative composition because formulations can change between manufacturers and markets.[1,3]

A commercial diazoxide liquid formulation may require the following excipient functions:

Formulation function	Candidate excipient strategy	Key development issue
Vehicle	Purified water with polyol support	Density, viscosity, microbial control
Wetting	Nonionic surfactant or polymeric wetting agent	Foaming, taste, safety in infants
Suspending	Cellulosic polymer, xanthan gum, acacia, or equivalent	Sedimentation and redispersion
Sweetening	Sorbitol, sucrose, or sugar-free system	Diarrhea, dental exposure, diabetes-related concerns
Humectancy	Glycerin or propylene glycol where justified	Osmolality and tolerability
Preservation	Methylparaben, propylparaben, benzoate, or alternative system	Pediatric exposure and preservative efficacy
Buffering	Citrate or similar buffer	pH stability and taste
Flavoring	Minimal fruit or masking flavor	Compatibility and pediatric acceptability
Chelation	EDTA or another chelator, if justified	Metal-ion control and regulatory acceptability

The preferred formulation should minimize unnecessary excipient complexity. Pediatric patients may receive diazoxide for months or years, so cumulative exposure, gastrointestinal effects, osmolality, sugar content, and preservative burden have greater commercial relevance than in a short-course medicine.

Can diazoxide be formulated as a true oral solution?

A true diazoxide oral solution is possible only if the formulation maintains complete dissolution at the target concentration across the labeled pH range and through long-term storage. The reference product’s suspension presentation indicates that a simple water-based solution is unlikely to be commercially practical at 50 mg/mL without a specialized solubilization approach.

What technical approaches can improve diazoxide solubility?

Potential approaches include:

1. pH adjustment to increase ionization, subject to chemical stability and tolerability limits.
2. Cosolvent systems using glycerin, polyethylene glycol, or other pharmaceutically accepted vehicles.
3. Surfactant-assisted solubilization.
4. Complexation with a suitable cyclodextrin or comparable carrier.
5. Amorphous or particle-engineered drug forms.
6. Concentrated liquid systems that are diluted before administration.

Each approach creates different regulatory and patent consequences. A cosolvent-heavy product may have unacceptable taste or gastrointestinal effects. A cyclodextrin formulation may improve solubility but increase cost and pediatric excipient scrutiny. A pH-driven formulation can create precipitation after dilution, during gastric exposure, or after temperature cycling.

A true solution should not be positioned as commercially superior until it demonstrates:

• Assay and degradation-product control.
• No precipitation during shelf life.
• Dose uniformity after storage.
• Acceptable taste and mouthfeel.
• Preservative efficacy where applicable.
• Compatibility with oral syringes and dosing accessories.
• Stability after opening.
• Comparable clinical performance or an acceptable bridge to the reference product.

What excipient strategy is strongest for a generic diazoxide product?

For a conventional abbreviated new drug application, the lowest-risk strategy is usually a suspension that closely matches the reference product’s critical quality attributes rather than a novel solution.

Recommended reference-aligned strategy

A practical development program would use:

• A controlled diazoxide particle-size distribution.
• A robust wetting system.
• A moderate-viscosity suspending vehicle.
• A preservative system supported by antimicrobial effectiveness testing.
• A non-sucrose sweetening system where possible.
• A calibrated oral syringe rather than a household spoon.
• A formulation pH and specific gravity close to the reference product.
• Packaging that limits sedimentation, evaporation, and microbial ingress.

The formulation should be designed around the marketed dose range. Pediatric patients may require small measured volumes, while adults may receive materially larger doses. A product that settles rapidly or forms a compact cake can create clinically meaningful dose variability.

What excipient risks could undermine a product?

The principal risks are:

• Excessive viscosity that prevents accurate syringe withdrawal.
• Rapid sedimentation that creates concentration gradients.
• Hard caking that resists shaking.
• High sorbitol or polyol content causing diarrhea.
• Strong preservative taste or local intolerance.
• Flavor instability during storage.
• Container-closure adsorption or extractables.
• Precipitation after freezing or heat exposure.
• Incompatibility with enteral feeding equipment.

For an infant and pediatric product, dose-delivery performance is a commercial differentiator. A slightly less elegant formulation with reliable redispersion and a well-designed syringe may have greater market value than a technically novel solution with difficult handling.

What is the FDA regulatory pathway for diazoxide oral liquid?

A conventional generic diazoxide oral suspension would generally be evaluated under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to establish pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA product-specific guidance and the dosage-form requirements applicable at submission.[4]

A materially different true solution may require a 505(b)(2) strategy if the applicant cannot rely entirely on the reference product’s safety and efficacy findings. The pathway depends on the degree of formulation difference, the ability to demonstrate equivalent exposure, and whether the FDA accepts a bridge based on comparative in vitro and pharmacokinetic data.

What FDA studies are likely to matter?

A development package should prioritize:

• Comparative assay and impurity profiles.
• Particle-size characterization for a suspension.
• Redispersibility and sedimentation testing.
• In vitro dissolution or drug-release characterization.
• Pharmacokinetic bioequivalence where required.
• In-use stability after opening.
• Microbial limits and antimicrobial effectiveness.
• Dose-delivery studies using the proposed syringe.
• Container-closure integrity.
• Extractables and leachables.
• Pediatric excipient justification.

FDA’s Inactive Ingredient Database can support excipient selection, but database precedent does not eliminate the need to justify concentration, route, dosage form, and patient population.[5]

What patents protect diazoxide oral solution products?

Diazoxide is an old active pharmaceutical ingredient, and the original compound patent position is no longer the principal barrier to entry. The commercial patent question concerns later patents directed to:

• Specific liquid compositions.
• Solubilized diazoxide systems.
• Particle engineering.
• Taste masking.
• Preservative combinations.
• Stable concentrated formulations.
• Dosing devices.
• Treatment methods using particular dosing schedules.
• Manufacturing processes and packaging.

The Orange Book should be reviewed for current patent and exclusivity listings associated with the reference product and any relevant approved product identifiers.[4] The public Proglycem labeling does not establish a current basic-compound exclusivity period. The practical market position is therefore likely to depend more on regulatory approval, supply reliability, formulation know-how, and contracting than on an unexpired diazoxide molecule patent.[1,4]

How strong is the formulation patent estate?

The likely strength of a formulation patent depends on claim specificity. Broad claims covering “diazoxide in an oral liquid” would face substantial prior-art risk because diazoxide liquid products have been marketed for decades. Narrower claims may be more defensible if they require:

• A defined diazoxide concentration.
• Specific pH and solvent ratios.
• A defined particle-size distribution.
• A particular preservative system.
• Long-term stability under specified conditions.
• A novel dosing device or administration method.

A new solution formulation may have stronger patent potential than a conventional suspension, but its claims must overcome prior art in pharmaceutical solubilization and liquid diazoxide products.

When does diazoxide lose exclusivity?

Diazoxide’s active-ingredient exclusivity expired long ago. No practical market exclusivity should be assumed from the molecule itself. Any current barrier would arise from product-specific patents, regulatory exclusivity, manufacturing rights, or commercial arrangements rather than from the original diazoxide compound.

Exclusivity category	Commercial assessment
Original compound patent	Expired
New chemical entity exclusivity	Not relevant
Conventional generic suspension	Potentially approvable if bioequivalence is established
Formulation patents	Possible, but claim scope must be validated
Method-of-use patents	Possible for defined treatment regimens, with limited effect on off-patent product supply
Orphan-drug exclusivity	Must be assessed against the specific product and indication; not assumed for all diazoxide uses
Biosimilar exclusivity	Not applicable because diazoxide is a small molecule

Are there Paragraph IV challenges to diazoxide oral suspension?

A Paragraph IV filing is possible for any listed patent that an ANDA applicant believes is invalid, unenforceable, or not infringed. The commercial significance depends on whether the Orange Book contains live patents covering the reference product.

For an old small-molecule product with limited apparent basic-compound protection, the more relevant generic strategy may be a standard ANDA supported by pharmaceutical equivalence and bioequivalence rather than a litigation-led Paragraph IV launch. Any Paragraph IV risk analysis must focus on current Orange Book listings, patent-use codes, notice letters, and district-court or Federal Circuit proceedings.[4,6]

No biosimilar pathway applies. Diazoxide is not a biologic, and competitors would pursue generic or 505(b)(2) pathways rather than biosimilar approval.

What commercial opportunities exist for diazoxide oral liquid?

1. Generic 50 mg/mL suspension

This is the most direct opportunity. A reliable generic could compete on:

• Lower acquisition cost.
• Consistent availability.
• Pharmacy wholesaler coverage.
• Better oral syringe packaging.
• Stable supply for specialty pharmacies and pediatric centers.

The addressable market is specialized rather than mass-market. The product can carry strategic value because treatment interruption in congenital hyperinsulinism is clinically consequential, while the number of competing suppliers may remain limited.

2. True oral solution

A true solution could provide:

• More uniform dosing without shaking.
• Easier administration through oral syringes.
• Better suitability for feeding tubes, if compatibility is demonstrated.
• A differentiated formulation for 505(b)(2) development.
• Potential licensing value if protected by composition and stability claims.

The solution opportunity has higher technical and regulatory risk than a generic suspension. Its commercial advantage must be demonstrated in administration studies rather than assumed from the dosage form alone.

3. Lower-sugar or preservative-reduced formulation

A product that reduces sucrose, sorbitol, or preservative exposure could appeal to pediatric specialists and caregivers. The commercial proposition is strongest if the formulation also improves taste, reduces gastrointestinal complaints, or supports longer in-use stability.

4. International supply and licensing

Diazoxide liquid products may have fragmented availability across the United States, Europe, and other markets. Licensing opportunities include:

• Regional commercialization rights.
• Contract manufacturing.
• Dual-source supply agreements.
• Hospital and specialty-pharmacy tenders.
• Pediatric formulation partnerships.
• Technology licensing for solubilization or dosing devices.

Geographic expansion requires separate assessment of local reference products, excipient permissions, labeling, pediatric indications, and medicine-shortage conditions.

What generic launch risks exist?

The main launch risks are commercial and executional:

Risk	Impact
Small patient population	Limits volume
Limited competitors	Can support price but may attract concentrated competition
Pediatric safety scrutiny	Extends development and review requirements
Suspension variability	Creates dose-uniformity and complaint risk
Active-ingredient supply	Can affect continuity and margins
Specialty distribution	Raises channel-management costs
Low reimbursement leverage	May limit premium pricing
Formulation patent claims	Can delay or narrow launch
Reference-product shortage	Increases opportunity but also raises supply expectations

Revenue exposure for the incumbent is likely concentrated in a narrow indication base rather than broad primary-care prescribing. That can make the product strategically important despite modest absolute sales. A new entrant should model volume by treated patient, average daily dose, duration of therapy, payer mix, and specialty-distribution discounts rather than by general oral-liquid market size.

How does diazoxide compare with competing hyperinsulinism treatments?

Diazoxide remains an important oral option for hyperinsulinemic hypoglycemia, but patients may also receive glucagon, octreotide, continuous glucose support, or surgery depending on the underlying disease and response.[1]

Product or approach	Role relative to diazoxide	Commercial implication
Diazoxide oral liquid	Chronic oral treatment for responsive hyperinsulinism	Specialized generic opportunity
Glucagon	Rescue or glucose-support role	Not a direct formulation substitute
Octreotide	Alternative or adjunct in selected patients	Competes clinically in refractory cases
Surgery	Definitive option for selected congenital disease	Reduces long-term drug demand in some patients
Continuous glucose delivery	Supportive management	May be used with or instead of drug therapy

Diazoxide’s competitive advantage is oral chronic use in patients who respond to it. Its limitation is that adverse effects and variable response can require alternative treatment.

Key Takeaways

• The reference U.S. product is diazoxide oral suspension, 50 mg/mL, not a confirmed true oral solution.
• A generic suspension is the lowest-risk development opportunity.
• A true solution offers stronger differentiation but requires a credible solubilization, stability, taste, and pediatric-tolerability package.
• The original diazoxide molecule is long off patent; current risk centers on formulation, method-of-use, packaging, and manufacturing claims.
• No biosimilar pathway applies.
• Commercial value depends on supply reliability, specialty distribution, pediatric dose accuracy, and formulation usability.
• A preservative-reduced, lower-sugar, syringe-optimized product could support premium positioning.
• A novel solution formulation may have licensing value if it delivers measurable administration or stability benefits and supports defensible patent claims.

FAQs

Is diazoxide oral solution the same as Proglycem?

No. Proglycem is labeled as a 50 mg/mL oral suspension. A true solution would require complete dissolution of diazoxide throughout shelf life and would represent a distinct formulation approach.[1]

What is the most attractive generic strength for diazoxide liquid?

The principal reference strength is 50 mg/mL. A generic matching that strength is the most direct ANDA opportunity, subject to FDA requirements and reference-product comparison.

Does diazoxide oral liquid need a preservative?

A multidose liquid generally requires a validated microbial-control strategy. That may involve a preservative system, packaging controls, or both. The selected approach must be supported by antimicrobial effectiveness and in-use stability data.

Can a diazoxide solution be marketed for congenital hyperinsulinism?

Potentially, but the regulatory pathway depends on formulation differences, indication reliance, bioequivalence, and the FDA’s acceptance of the supporting data. A materially different solution may require a 505(b)(2) application rather than a conventional ANDA.

Is diazoxide a biosimilar opportunity?

No. Diazoxide is a small-molecule drug. Competitors would pursue generic, hybrid, or 505(b)(2) approval pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (2023). Proglycem (diazoxide) oral suspension prescribing information.
2. National Library of Medicine. (2024). Diazoxide: Drug information and product labeling. DailyMed.
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
5. U.S. Food and Drug Administration. (2024). Guidance for industry: Inactive ingredient database.
6. U.S. Food and Drug Administration. (2024). Approved drug product and patent listing resources for generic drug applicants.